Quantcast

Latest Japanese encephalitis Stories

2014-07-19 12:20:43

DALLAS, July 19, 2014 /PRNewswire/ -- MarketReportsOnline.com offers "2013 Deep Research Report on China Japanese Encephalitis Vaccine Industry" in its store. Companies like Chengdu Institute of Biological Products Co. Ltd, Wuhan Institute of Biological Products Co. Ltd, Lanzhou Institute of Biological Products Co. Ltd, Beijing Tiantan Biological Products Co. Ltd and Liaoning Chengda Biotechnology are profiled in this report available at...

2013-05-14 23:00:40

MarketResearchReports.Biz announces addition of new report “Global Critical Care Market to 2019” to its database. Buy the copy of this report visit - http://www.marketresearchreports.biz/analysis-details/critical-care-market-to-2019-growth-from-factor-concentrates-new-indications-and-increasing-demand-for-albumin-in-asia-pacific Albany, NY (PRWEB) May 15, 2013 GBI Research, the leading business intelligence provider, has released its latest research, “Critical Care Market...

2013-04-12 15:54:36

Researchers have discovered that rising temperature induces key changes in the dengue virus when it enters its human host, and the findings represent a new approach for designing vaccines against the aggressive mosquito-borne pathogen. The researchers found that the dengue virus particles swell slightly and take on a bumpy appearance when heated to human body temperature, exposing "epitopes," or regions where antibodies could attach to neutralize the virus. The discovery is significant...

2011-05-05 01:53:00

VIENNA, May 5, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that the company's Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO) for Intercell, effective May 10, 2011. At the same time, Gerd Zettlmeissl, current CEO, will resign to pursue other personal and professional interests. Under his excellent leadership, Intercell received international approval for the novel Japanese Encephalitis vaccine,...

2011-03-01 01:35:00

VIENNA, March 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs. Increase in IXIARO®/JESPECT® sales by approximately 66% to EUR 12.8m for the full year 2010, due to increased sales in key travel markets and to U.S. military. EUR 255.2m net loss for the full year 2010 resulting mainly from...

2010-11-09 01:51:00

VIENNA, Nov. 9, 2010 /PRNewswire-FirstCall/ -- Today, Intercell AG (VSE: ICLL) announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board. Financial Results IXIARO and JESPECT sales revenues continue showing significant year-on-year growth - sales revenues totaled EUR 9.4m in the 9 months ended September 30, 2010, compared to EUR 5.6m in the same period of the previous year....

2010-08-17 01:40:00

VIENNA, Aug. 17 /PRNewswire-FirstCall/ -- Today, Intercell AG (VSE: ICLL) announced its financial results for Q2 and H1 2010. IXIARO®/JESPECT® sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 - Continued focus on growing marketing and sales of product in traveler and military markets Revenues from IXIARO/JESPECT product sales in Q2 2010 represent the best quarterly sales since the product launch in Q1 2009. The Company...

2010-05-11 01:53:00

VIENNA, May 11 /PRNewswire-FirstCall/ -- Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's development programs. Financial Results EUR 4.8m revenues in Q1 2010 compared to EUR 5.4m in Q1 2009. IXIARO®/JESPECT® product sales in line with Q1 2009 reflecting low level of new product supplies in Q1 2010; new product supplies to marketing and distribution partners...

2010-04-22 06:00:00

VIENNA, April 22 /PRNewswire/ -- Intercell AG (VSE; "ICLL") today announced that members of the management team presented at the World Vaccine Congress on innovation, the company's Ixiaro® vaccine, and development and regulatory challenges, held April 19-22 near Washington, DC. During the congress, on April 20, 2010, Dr. Gerd Zettlmeissl, chief executive officer, Intercell received a Vaccine Industry Excellence Award for Biotech CEO of the Year. "It is a great honor to...


Latest Japanese encephalitis Reference Libraries

45_bc02a98a30585718c34a7eee0900e51d
2011-02-25 18:53:25

West Nile virus (WNV) is a virus of the family Flaviviridae. It is part of the Japanese encephalitis antigenic complex of viruses and is found in both tropical and temperate regions. It primarily infects birds but can infect humans, horses, dogs, cats, bats, and other mammals. Humans are generally infected through the bites of mosquitoes and about 90% of West Nile Virus infections are without symptoms. The virion is 45-60 nm and covered with a relatively smooth protein surface. It is...

70_9faa4fdd7b99b05bdbb88a7039ba302a
2011-02-23 21:04:53

St. Louis Encephalitis is a disease caused by the Culex mosquito borne St. Louis Encephalitis virus. It is related to Japanese encephalitis virus and is a member of the Flaviviridae subgroup. It mainly affects the United States and occasionally hits Canada and Mexico. The name goes back to 1933 within five weeks in autumn an encephalitis epidemic of explosive proportions broke out in the vicinity of St. Louis, Missouri. Over 1000 cases were reported and the National Institute of Health...

More Articles (2 articles) »
Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related